LoginSignup
ITC

Intra-Cellular

Stock
Stock
ISIN: US46116X1019
Ticker: ITCI
US46116X1019
ITCI

Price

Price

CHART BY

Frequently asked questions

What is Intra-Cellular's market capitalization?

The market capitalization of Intra-Cellular is $13.44B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Intra-Cellular?

Intra-Cellular's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.86. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Intra-Cellular's stock?

Currently, 14 analysts cover Intra-Cellular's stock, with a consensus target price of $123.55. Analyst ratings provide insights into the stock's expected performance.

What is Intra-Cellular's revenue over the trailing twelve months?

Over the trailing twelve months, Intra-Cellular reported a revenue of $613.73M.

What is the EBITDA for Intra-Cellular?

Intra-Cellular's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$121.09M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Intra-Cellular?

Intra-Cellular has a free cash flow of -$62.91M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Intra-Cellular have, and what sector and industry does it belong to?

Intra-Cellular employs approximately 610 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Major industry.

What is the free float of Intra-Cellular's shares?

The free float of Intra-Cellular is 99.30M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$13.44B
EPS (TTM) 
-$0.86
Free Float 
99.30M
Revenue (TTM) 
$613.73M
EBITDA (TTM) 
-$121.09M
Free Cashflow (TTM) 
-$62.91M

Pricing

1D span
$125.94$126.98
52W span
$62.88$128.00

Analyst Ratings

The price target is $123.55 and the stock is covered by 14 analysts.

Buy

5

Hold

9

Sell

0

Information

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

Employees
610
Industries
Pharmaceuticals: Major
Sector
Health Care

Identifier

ISIN
US46116X1019
Primary Ticker
ITCI

Knockouts

Join the conversation
Sign upLogin